European osteoarthritis therapeutics market is estimated to grow at a CAGR of 8.0% during the forecast period. Funding opportunity for osteoarthritis study is expected to offer an opportunity for new launches of osteoarthritis drugs. For instance, in August 2020, Bone Therapeutics granted nearly $1.2 million for the advances of its current pivotal phase III clinical study with the enriched protein solution, JTA-004. This trial aims to assess the potential of a single, intra-articular injection of JTA-004 to decrease knee osteoarthritic pain than placebo or Hylan G-F 20, which is a crucial existing osteoarthritis treatment available on the market. This study is being performed in six European countries and Hong Kong SAR. This particular financial support will offer additional support in further advancing its phase III trial in osteoarthritis of the knee. The study is intended to confirm the safety and efficacy of JTA-004 in terms of commercialization as a potentially new and much-required therapeutics option for the massive patient population base.
Browse the full report description European Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report, By Anatomy (Knee, Ankle, Hip, Hand, and Spine), By Drug Type (NSAIDs, Viscosupplementation Agents, Corticosteroids, and Analgesics) and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/europe-osteoarthritis-therapeutics-market
Further, in May 2020, a novel cell test is developed for osteoarthritis drugs named O-POINTED, an EU funded project. It is a cell test that supports pharmaceutical and biomedical firms to use a personalized approach for drug development for the first time. The test is based on cell lines produced from a cohort of more than 50 osteoarthritis patients, obtained from diverse patient subpopulations through tissue exams. To test new drugs, the cell lines are genetically engineered that can be easily handled in the lab. These kinds of initiatives will facilitate biopharmaceutical firms to develop potential drugs for osteoarthritis treatment in the region. As a result, the drug developed with a personalized approach is expected to be useful for patients suffering from osteoarthritis.
Scope of the European Osteoarthritis Therapeutics Market
Market Coverage
Key questions addressed by the report
o Recovery Timeline
o Deviation from the pre-COVID-19 forecast
o Most affected segment
European Osteoarthritis Therapeutics Market-Segmentation
By Anatomy
By Drug Type
European Osteoarthritis Therapeutics Market– Segment by Country
To learn more about this report request a free sample copy
@ https://www.omrglobal.com/request-sample/europe-osteoarthritis-therapeutics-market